Literature DB >> 19364650

Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.

Rahul S Nandurdikar1, Anna E Maciag, Michael L Citro, Paul J Shami, Larry K Keefer, Joseph E Saavedra, Harinath Chakrapani.   

Abstract

Here we report a number of novel JS-K structural analogues with sub-micromolar anti-proliferative activities against human leukemia cell lines HL-60 and U937; JS-K is the anti-cancer lead compound O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate. The ability of these compounds to generate intracellular nitric oxide correlated well with their observed anti-proliferative effects: analogues that had potent inhibitory activity against leukemia cells formed elevated levels of intracellular nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364650      PMCID: PMC2755573          DOI: 10.1016/j.bmcl.2009.03.115

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.

Authors:  Zhenggang Ren; Siddhartha Kar; Ziqiu Wang; Meifang Wang; Joseph E Saavedra; Brian I Carr
Journal:  J Cell Physiol       Date:  2003-12       Impact factor: 6.384

2.  JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.

Authors:  Vidya Udupi; Margaret Yu; Swati Malaviya; Joseph E Saavedra; Paul J Shami
Journal:  Leuk Res       Date:  2006-01-24       Impact factor: 3.156

3.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

4.  Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.

Authors:  Paul J Shami; Joseph E Saavedra; Challice L Bonifant; Jingxi Chu; Vidya Udupi; Swati Malaviya; Brian I Carr; Siddhartha Kar; Meifeng Wang; Lee Jia; Xinhua Ji; Larry K Keefer
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

5.  JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.

Authors:  Paul J Shami; Joseph E Saavedra; Lai Y Wang; Challice L Bonifant; Bhalchandra A Diwan; Shivendra V Singh; Yijun Gu; Stephen D Fox; Gregory S Buzard; Michael L Citro; David J Waterhouse; Keith M Davies; Xinhua Ji; Larry K Keefer
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

6.  JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Authors:  Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson
Journal:  Blood       Date:  2007-03-23       Impact factor: 22.113

7.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

8.  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Ravi C Kalathur; Anna E Maciag; Michael L Citro; Xinhua Ji; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2008-09-30       Impact factor: 3.641

9.  Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.

Authors:  J Kitagaki; Y Yang; J E Saavedra; N H Colburn; L K Keefer; A O Perantoni
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

10.  TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.

Authors:  Ann-Marie Simeone; Vanity McMurtry; René Nieves-Alicea; Joseph E Saavedra; Larry K Keefer; Marcella M Johnson; Ana M Tari
Journal:  Breast Cancer Res       Date:  2008-05-12       Impact factor: 6.466

View more
  4 in total

1.  "Click" reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donors.

Authors:  Oyebola A Oladeinde; Sam Y Hong; Ryan J Holland; Anna E Maciag; Larry K Keefer; Joseph E Saavedra; Rahul S Nandurdikar
Journal:  Org Lett       Date:  2010-10-01       Impact factor: 6.005

2.  Nitrogen-bound diazeniumdiolated amidines.

Authors:  Debanjan Biswas; Jeffrey R Deschamps; Larry K Keefer; Joseph A Hrabie
Journal:  Chem Commun (Camb)       Date:  2010-06-30       Impact factor: 6.222

3.  Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.

Authors:  Rahul S Nandurdikar; Anna E Maciag; Ryan J Holland; Zhao Cao; Paul J Shami; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2012-03-09       Impact factor: 3.641

4.  JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.

Authors:  Xudong Zhao; Aizhen Cai; Zheng Peng; Wenquan Liang; Hongqing Xi; Peiyu Li; Guozhu Chen; Jiyun Yu; Lin Chen
Journal:  J Cell Mol Med       Date:  2019-01-22       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.